| Audit Committee | Position |
|---|---|
|
John Ciccio is President and CEO of Adheris Health, a MedAdvisor company. Adheris provides dynamic patient management solutions that activate patients, improve outcomes and elevate brand performance with customized patient behavioral models built on extensive data insights and analytics. Prior to joining Adheris Health, Mr. Ciccio served as President of the healthcare professional social network Skipta, which he helped lead to exponential growth and eventual sale. Mr. Ciccio has also worked closely with several top 10 pharma companies to develop product launch strategies in the US and Europe. Mr. Ciccio received his undergraduate degree from Harvard University. |
Chair
|
|
Mr. Jarry is currently the Co-founder and Chief Executive Officer of Libera Bio S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therapeutics to address intracellular cancer targets, since April 2018. He also serves as the Chief Operating Officer of Advantage Therapeutics Inc., an investigational-stage company focused on the diseases of aging, since May 2023 and as Chief Financial Officer of Rational Vaccines, Inc., an investigational-stage infectious disease company focused on combating herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections, since August 2021. Mr. Jarry served as an advisor to DarioHealth Corp. (Nasdaq: DRIO) from November 2016 to September 2017, and then as its President and Chief Commercial Officer until January 2020. Between 2015 and 2016, he served as Senior Vice President of the Consumer Sector and Officer at Intrexon Corp. (NYSE: XON), a biotechnology company focused on engineering biological systems to enable DNA-based control over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for Bristol-Myers Squibb (NYSE: BMY), where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Prior to that, between 2009 and 2010, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC. Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr. Jarry served in several leadership roles at Novartis International AG (NYSE: NVS), including working as Global Division Head of Strategy, Business Development & Licensing at Novartis Headquarters in Switzerland, Senior Vice President and Region Head for Latin America and for Asia-Pacific for Novartis’ Consumer Health Division, Head of India Rural Business and Head of Western/Eastern Europe, Russia, CIS - Vaccines division. Mr. Jarry holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from Délégation Générale pour l’Armement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and Hautes Études Commerciales Paris. Mr. Jarry’s more than 40 years of building fast-growing companies in neuroimmunology, oncology, cell & gene therapy, synthetic biology and digital therapeutics makes him well qualified as a member of the Board. |
Member
|
|
Dr. Theodore Search, Pharm. D. is the General Manager and CEO of Real-World Data for Norstella. Prior to his role at Norstella, Ted served as the CEO of Real-World Networks- Pharma Intelligence at Informa and was the Founder and CEO of Skipta, now a Norstella Company. Ted is an innovation advocate, tech guru, and expert in Real-World Evidence. He has been invited to speak at various conferences around the country and named amongst the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and amongst the Top 100 Elite Entrepreneurs in the pharmaceutical and healthcare industry in 2016. Ted holds a Doctor of Pharmacy degree from the University of Pittsburgh, is a board licensed Pharmacist in the Commonwealth of Pennsylvania and has benefited from practical pharmacy experience in both the retail and clinical settings. |
Member
|
| Compensation Committee | Position |
|---|---|
|
Dr. Theodore Search, Pharm. D. is the General Manager and CEO of Real-World Data for Norstella. Prior to his role at Norstella, Ted served as the CEO of Real-World Networks- Pharma Intelligence at Informa and was the Founder and CEO of Skipta, now a Norstella Company. Ted is an innovation advocate, tech guru, and expert in Real-World Evidence. He has been invited to speak at various conferences around the country and named amongst the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and amongst the Top 100 Elite Entrepreneurs in the pharmaceutical and healthcare industry in 2016. Ted holds a Doctor of Pharmacy degree from the University of Pittsburgh, is a board licensed Pharmacist in the Commonwealth of Pennsylvania and has benefited from practical pharmacy experience in both the retail and clinical settings. |
Chair
|
|
John Ciccio is President and CEO of Adheris Health, a MedAdvisor company. Adheris provides dynamic patient management solutions that activate patients, improve outcomes and elevate brand performance with customized patient behavioral models built on extensive data insights and analytics. Prior to joining Adheris Health, Mr. Ciccio served as President of the healthcare professional social network Skipta, which he helped lead to exponential growth and eventual sale. Mr. Ciccio has also worked closely with several top 10 pharma companies to develop product launch strategies in the US and Europe. Mr. Ciccio received his undergraduate degree from Harvard University. |
Member
|
|
Mr. Jarry is currently the Co-founder and Chief Executive Officer of Libera Bio S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therapeutics to address intracellular cancer targets, since April 2018. He also serves as the Chief Operating Officer of Advantage Therapeutics Inc., an investigational-stage company focused on the diseases of aging, since May 2023 and as Chief Financial Officer of Rational Vaccines, Inc., an investigational-stage infectious disease company focused on combating herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections, since August 2021. Mr. Jarry served as an advisor to DarioHealth Corp. (Nasdaq: DRIO) from November 2016 to September 2017, and then as its President and Chief Commercial Officer until January 2020. Between 2015 and 2016, he served as Senior Vice President of the Consumer Sector and Officer at Intrexon Corp. (NYSE: XON), a biotechnology company focused on engineering biological systems to enable DNA-based control over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for Bristol-Myers Squibb (NYSE: BMY), where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Prior to that, between 2009 and 2010, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC. Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr. Jarry served in several leadership roles at Novartis International AG (NYSE: NVS), including working as Global Division Head of Strategy, Business Development & Licensing at Novartis Headquarters in Switzerland, Senior Vice President and Region Head for Latin America and for Asia-Pacific for Novartis’ Consumer Health Division, Head of India Rural Business and Head of Western/Eastern Europe, Russia, CIS - Vaccines division. Mr. Jarry holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from Délégation Générale pour l’Armement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and Hautes Études Commerciales Paris. Mr. Jarry’s more than 40 years of building fast-growing companies in neuroimmunology, oncology, cell & gene therapy, synthetic biology and digital therapeutics makes him well qualified as a member of the Board. |
Member
|
| Nominating and Corporate Governance Committee | Position |
|---|---|
|
John Ciccio is President and CEO of Adheris Health, a MedAdvisor company. Adheris provides dynamic patient management solutions that activate patients, improve outcomes and elevate brand performance with customized patient behavioral models built on extensive data insights and analytics. Prior to joining Adheris Health, Mr. Ciccio served as President of the healthcare professional social network Skipta, which he helped lead to exponential growth and eventual sale. Mr. Ciccio has also worked closely with several top 10 pharma companies to develop product launch strategies in the US and Europe. Mr. Ciccio received his undergraduate degree from Harvard University. |
Chair
|
|
Ms. McKean Dieser is currently the Vice President, Head of Legal Patient Evidence of UCB, Inc., a subsidiary of UCB, S.A., a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system, since August 2016, and previously from April 2008 to April 2013. At UCB, she leads a team of attorneys supporting UCB’s global assets, global payer functions, and regulatory, medical and patient communities, including clinical development. Ms. McKean Dieser was formerly a member of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing lawyer for all pharmaceutical and combination products from May 2013 to July 2016. Prior to joining the pharmaceutical industry, Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Prior to receiving her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division and a B.A. degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January 2024 at the age of 21. Ms. McKean Dieser is well qualified to serve as a director of the Company due to her substantial knowledge of the pharmaceutical regulatory and commercialization environment and more than 21 years of working experience in corporate controls and governance. |
Member
|
|
Dr. Theodore Search, Pharm. D. is the General Manager and CEO of Real-World Data for Norstella. Prior to his role at Norstella, Ted served as the CEO of Real-World Networks- Pharma Intelligence at Informa and was the Founder and CEO of Skipta, now a Norstella Company. Ted is an innovation advocate, tech guru, and expert in Real-World Evidence. He has been invited to speak at various conferences around the country and named amongst the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and amongst the Top 100 Elite Entrepreneurs in the pharmaceutical and healthcare industry in 2016. Ted holds a Doctor of Pharmacy degree from the University of Pittsburgh, is a board licensed Pharmacist in the Commonwealth of Pennsylvania and has benefited from practical pharmacy experience in both the retail and clinical settings. |
Member
|
John Ciccio
John Ciccio is President and CEO of Adheris Health, a MedAdvisor company. Adheris provides dynamic patient management solutions that activate patients, improve outcomes and elevate brand performance with customized patient behavioral models built on extensive data insights and analytics. Prior to joining Adheris Health, Mr. Ciccio served as President of the healthcare professional social network Skipta, which he helped lead to exponential growth and eventual sale. Mr. Ciccio has also worked closely with several top 10 pharma companies to develop product launch strategies in the US and Europe. Mr. Ciccio received his undergraduate degree from Harvard University.
Olivier R. Jarry
Mr. Jarry is currently the Co-founder and Chief Executive Officer of Libera Bio S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therapeutics to address intracellular cancer targets, since April 2018. He also serves as the Chief Operating Officer of Advantage Therapeutics Inc., an investigational-stage company focused on the diseases of aging, since May 2023 and as Chief Financial Officer of Rational Vaccines, Inc., an investigational-stage infectious disease company focused on combating herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections, since August 2021.
Mr. Jarry served as an advisor to DarioHealth Corp. (Nasdaq: DRIO) from November 2016 to September 2017, and then as its President and Chief Commercial Officer until January 2020. Between 2015 and 2016, he served as Senior Vice President of the Consumer Sector and Officer at Intrexon Corp. (NYSE: XON), a biotechnology company focused on engineering biological systems to enable DNA-based control over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for Bristol-Myers Squibb (NYSE: BMY), where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Prior to that, between 2009 and 2010, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC. Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr. Jarry served in several leadership roles at Novartis International AG (NYSE: NVS), including working as Global Division Head of Strategy, Business Development & Licensing at Novartis Headquarters in Switzerland, Senior Vice President and Region Head for Latin America and for Asia-Pacific for Novartis’ Consumer Health Division, Head of India Rural Business and Head of Western/Eastern Europe, Russia, CIS - Vaccines division.
Mr. Jarry holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from Délégation Générale pour l’Armement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and Hautes Études Commerciales Paris.
Mr. Jarry’s more than 40 years of building fast-growing companies in neuroimmunology, oncology, cell & gene therapy, synthetic biology and digital therapeutics makes him well qualified as a member of the Board.
Theodore Search
Dr. Theodore Search, Pharm. D. is the General Manager and CEO of Real-World Data for Norstella. Prior to his role at Norstella, Ted served as the CEO of Real-World Networks- Pharma Intelligence at Informa and was the Founder and CEO of Skipta, now a Norstella Company.
Ted is an innovation advocate, tech guru, and expert in Real-World Evidence. He has been invited to speak at various conferences around the country and named amongst the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and amongst the Top 100 Elite Entrepreneurs in the pharmaceutical and healthcare industry in 2016.
Ted holds a Doctor of Pharmacy degree from the University of Pittsburgh, is a board licensed Pharmacist in the Commonwealth of Pennsylvania and has benefited from practical pharmacy experience in both the retail and clinical settings.
Theodore Search
Dr. Theodore Search, Pharm. D. is the General Manager and CEO of Real-World Data for Norstella. Prior to his role at Norstella, Ted served as the CEO of Real-World Networks- Pharma Intelligence at Informa and was the Founder and CEO of Skipta, now a Norstella Company.
Ted is an innovation advocate, tech guru, and expert in Real-World Evidence. He has been invited to speak at various conferences around the country and named amongst the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and amongst the Top 100 Elite Entrepreneurs in the pharmaceutical and healthcare industry in 2016.
Ted holds a Doctor of Pharmacy degree from the University of Pittsburgh, is a board licensed Pharmacist in the Commonwealth of Pennsylvania and has benefited from practical pharmacy experience in both the retail and clinical settings.
John Ciccio
John Ciccio is President and CEO of Adheris Health, a MedAdvisor company. Adheris provides dynamic patient management solutions that activate patients, improve outcomes and elevate brand performance with customized patient behavioral models built on extensive data insights and analytics. Prior to joining Adheris Health, Mr. Ciccio served as President of the healthcare professional social network Skipta, which he helped lead to exponential growth and eventual sale. Mr. Ciccio has also worked closely with several top 10 pharma companies to develop product launch strategies in the US and Europe. Mr. Ciccio received his undergraduate degree from Harvard University.
Olivier R. Jarry
Mr. Jarry is currently the Co-founder and Chief Executive Officer of Libera Bio S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therapeutics to address intracellular cancer targets, since April 2018. He also serves as the Chief Operating Officer of Advantage Therapeutics Inc., an investigational-stage company focused on the diseases of aging, since May 2023 and as Chief Financial Officer of Rational Vaccines, Inc., an investigational-stage infectious disease company focused on combating herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections, since August 2021.
Mr. Jarry served as an advisor to DarioHealth Corp. (Nasdaq: DRIO) from November 2016 to September 2017, and then as its President and Chief Commercial Officer until January 2020. Between 2015 and 2016, he served as Senior Vice President of the Consumer Sector and Officer at Intrexon Corp. (NYSE: XON), a biotechnology company focused on engineering biological systems to enable DNA-based control over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as the Head of Strategy, Operations and Market Access, focusing on Emerging Markets, for Bristol-Myers Squibb (NYSE: BMY), where he oversaw the product launch and growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Prior to that, between 2009 and 2010, Mr. Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals LLC. Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr. Jarry served in several leadership roles at Novartis International AG (NYSE: NVS), including working as Global Division Head of Strategy, Business Development & Licensing at Novartis Headquarters in Switzerland, Senior Vice President and Region Head for Latin America and for Asia-Pacific for Novartis’ Consumer Health Division, Head of India Rural Business and Head of Western/Eastern Europe, Russia, CIS - Vaccines division.
Mr. Jarry holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from Délégation Générale pour l’Armement, and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and Hautes Études Commerciales Paris.
Mr. Jarry’s more than 40 years of building fast-growing companies in neuroimmunology, oncology, cell & gene therapy, synthetic biology and digital therapeutics makes him well qualified as a member of the Board.
John Ciccio
John Ciccio is President and CEO of Adheris Health, a MedAdvisor company. Adheris provides dynamic patient management solutions that activate patients, improve outcomes and elevate brand performance with customized patient behavioral models built on extensive data insights and analytics. Prior to joining Adheris Health, Mr. Ciccio served as President of the healthcare professional social network Skipta, which he helped lead to exponential growth and eventual sale. Mr. Ciccio has also worked closely with several top 10 pharma companies to develop product launch strategies in the US and Europe. Mr. Ciccio received his undergraduate degree from Harvard University.
Avril McKean Dieser
Ms. McKean Dieser is currently the Vice President, Head of Legal Patient Evidence of UCB, Inc., a subsidiary of UCB, S.A., a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system, since August 2016, and previously from April 2008 to April 2013. At UCB, she leads a team of attorneys supporting UCB’s global assets, global payer functions, and regulatory, medical and patient communities, including clinical development. Ms. McKean Dieser was formerly a member of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing lawyer for all pharmaceutical and combination products from May 2013 to July 2016.
Prior to joining the pharmaceutical industry, Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Prior to receiving her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division and a B.A. degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January 2024 at the age of 21.
Ms. McKean Dieser is well qualified to serve as a director of the Company due to her substantial knowledge of the pharmaceutical regulatory and commercialization environment and more than 21 years of working experience in corporate controls and governance.
Theodore Search
Dr. Theodore Search, Pharm. D. is the General Manager and CEO of Real-World Data for Norstella. Prior to his role at Norstella, Ted served as the CEO of Real-World Networks- Pharma Intelligence at Informa and was the Founder and CEO of Skipta, now a Norstella Company.
Ted is an innovation advocate, tech guru, and expert in Real-World Evidence. He has been invited to speak at various conferences around the country and named amongst the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and amongst the Top 100 Elite Entrepreneurs in the pharmaceutical and healthcare industry in 2016.
Ted holds a Doctor of Pharmacy degree from the University of Pittsburgh, is a board licensed Pharmacist in the Commonwealth of Pennsylvania and has benefited from practical pharmacy experience in both the retail and clinical settings.